NIHR Signal: Eplerenone does not improve vision in people with central serous chorioretinopathy (CSC)
Expert commentary is provided for a trial of 114 adults with CSC for ≥4 months, without any previous treatment, which found eplerenone was not associated with any clinically important or statistically significant difference to placebo in terms of visual acuity at 12 months.
Source:
NIHR Dissemination Centre